Asthma | China In-Depth | China | 2022
Asthma is a common chronic airway disease that affects children and adults. Environmental factors and a rapidly changing lifestyle have increased the incidence and prevalence of asthma in China. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair / Seretide, AstraZeneca’s Symbicort), oral drugs (montelukast), and biologics (Roche / Novartis’s Xolair). However, the market is evolving as generic alternatives to inhaled blockbuster agents continue to launch. Novel targeted therapies—benralizumab (AstraZeneca’s Fasenra) and mepolizumab (GSK’s Nucala)—are also in late-phase development in China for asthma. The launch and uptake of these agents will lead to significant growth of China’s asthma therapy market over 2021-2031. In addition, ongoing reforms in China’s regulatory and access and reimbursement landscape will increasingly encourage multinational companies to enter the market.
- How large is China’s drug-treatable asthma population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s asthma market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the asthma pipeline in China? What sales could they secure in asthma? What are interviewed experts’ opinions of these therapies?
- What are the key drivers of and constraints in China’s asthma therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Release date
December 2022
Geography
China
Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 25 pulmonologists and 25 PCPs.
Epidemiology
Diagnosed prevalence of asthma in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales, and patient share of key asthma therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 6 drugs; Phase II: 3 drugs; coverage of Phase I products.
